Ranolazine, Ethnicity and the Metabolic Syndrome
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 160 participants.
Also called NCT01304095
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 160 participants
- Sponsor
- Registry
-
NCT01304095
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Unknown status
Technical summary
Registry record NCT01304095. Randomized; no masking; primary purpose treatment. Start 2011-01 (registry gives no type); primary completion 2013-07 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Ranolazine, Ethnicity and the Metabolic Syndrome
- Acronym
- REMS
- Condition
- Coronary Artery Disease
- Condition
- Angina
- Condition
- Metabolic Syndrome
- Intervention (Drug)
- Ranolazine
- Lead sponsor
- Atlanta Heart Specialists, LLC
- Collaborator
- Gilead Sciences
Record details
- Record id
cardio:ct-nct01304095- Content hash
2eee1cc3246e5210f7f2d96fe4b925604e4652c8c776267ebc4cdd72b8bda665